Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.
2.

Molecular mechanisms of neurotoxicity of pathological prion protein.

Castilla J, Hetz C, Soto C.

Curr Mol Med. 2004 Jun;4(4):397-403. Review.

PMID:
15354870
3.

Molecular Mechanism of the Misfolding and Oligomerization of the Prion Protein: Current Understanding and Its Implications.

Singh J, Udgaonkar JB.

Biochemistry. 2015 Jul 28;54(29):4431-42. doi: 10.1021/acs.biochem.5b00605. Review.

PMID:
26171558
4.

Prion diseases: what is the neurotoxic molecule?

Chiesa R, Harris DA.

Neurobiol Dis. 2001 Oct;8(5):743-63. Review.

PMID:
11592845
5.

Molecular mechanisms of neurodegeneration mediated by dysfunctional subcellular organelles in transmissible spongiform encephalopathies.

Song Z, Zhao D, Yang L.

Acta Biochim Biophys Sin (Shanghai). 2013 Jun;45(6):452-64. doi: 10.1093/abbs/gmt014. Review. Erratum in: Acta Biochim Biophys Sin (Shanghai). 2014 Jul;46(7):627.

PMID:
23439666
6.

Protein misfolding and disease: the case of prion disorders.

Hetz C, Soto C.

Cell Mol Life Sci. 2003 Jan;60(1):133-43. Review.

PMID:
12613663
7.

Thienyl pyrimidine derivatives with PrP(Sc) oligomer-inducing activity are a promising tool to study prions.

Imberdis T, Ayrolles-Torro A, Verdier JM, Perrier V.

Curr Top Med Chem. 2013;13(19):2477-83. Review.

PMID:
24059332
8.

Prion protein self-interactions: a gateway to novel therapeutic strategies?

Rigter A, Langeveld JP, van Zijderveld FG, Bossers A.

Vaccine. 2010 Nov 16;28(49):7810-23. doi: 10.1016/j.vaccine.2010.09.012. Review.

PMID:
20932496
9.

Prion protein misfolding and disease.

Moore RA, Taubner LM, Priola SA.

Curr Opin Struct Biol. 2009 Feb;19(1):14-22. doi: 10.1016/j.sbi.2008.12.007. Review.

10.

Prion diseases and their biochemical mechanisms.

Cobb NJ, Surewicz WK.

Biochemistry. 2009 Mar 31;48(12):2574-85. doi: 10.1021/bi900108v. Review.

11.

Cellular and sub-cellular pathology of animal prion diseases: relationship between morphological changes, accumulation of abnormal prion protein and clinical disease.

Jeffrey M, McGovern G, Sisó S, González L.

Acta Neuropathol. 2011 Jan;121(1):113-34. doi: 10.1007/s00401-010-0700-3. Review.

PMID:
20532540
12.

Prion protein misfolding.

Kupfer L, Hinrichs W, Groschup MH.

Curr Mol Med. 2009 Sep;9(7):826-35. Review.

13.

Mechanisms of prion-induced neurodegeneration.

Saá P, Harris DA, Cervenakova L.

Expert Rev Mol Med. 2016 Apr 8;18:e5. doi: 10.1017/erm.2016.8. Review.

PMID:
27055367
14.

Prion protein interconversions and the transmissible spongiform encephalopathies.

Horiuchi M, Caughey B.

Structure. 1999 Oct 15;7(10):R231-40. Review.

15.

Prion proteins meet protein quality control.

Dimcheff DE, Portis JL, Caughey B.

Trends Cell Biol. 2003 Jul;13(7):337-40. Review.

PMID:
12837603
16.

Cyclic amplification of protein misfolding: application to prion-related disorders and beyond.

Soto C, Saborio GP, Anderes L.

Trends Neurosci. 2002 Aug;25(8):390-4. Review.

PMID:
12127750
17.

The highways and byways of prion protein trafficking.

Campana V, Sarnataro D, Zurzolo C.

Trends Cell Biol. 2005 Feb;15(2):102-11. Review.

PMID:
15695097
18.

Evolving views in prion glycosylation: functional and pathological implications.

Ermonval M, Mouillet-Richard S, Codogno P, Kellermann O, Botti J.

Biochimie. 2003 Jan-Feb;85(1-2):33-45. Review.

PMID:
12765773
19.

Folding and misfolding of the prion protein in the secretory pathway.

Tatzelt J, Winklhofer KF.

Amyloid. 2004 Sep;11(3):162-72. Review.

PMID:
15523918
20.

Defining the limits of prion disease.

Ridley RM.

Neuropathol Appl Neurobiol. 1994 Aug;20(4):339-43. Review.

PMID:
7808583

Supplemental Content

Support Center